Misplaced Pages

Lomitapide: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively
Page 1
Page 2
← Previous editContent deleted Content addedVisualWikitext
Revision as of 01:16, 12 August 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per Chem/Drugbox validation← Previous edit Latest revision as of 11:57, 13 August 2023 edit undoOAbot (talk | contribs)Bots442,978 editsm Open access bot: doi added to citation with #oabot. 
(60 intermediate revisions by 41 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{drugbox
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 444364270
| image = Lomitapide_skeletal.svg

<!--Clinical data-->
| pronounce =
| tradename = Juxtapid (US), Lojuxta (EU)
| Drugs.com =
| MedlinePlus =
| licence_EU = yes
| DailyMedID = Lomitapide
| licence_US = Lomitapide
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_category =
| routes_of_administration = ]
| ATC_prefix = C10
| ATC_suffix = AX12
| ATC_supplemental =

| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = Rx-only
| legal_US_comment = <ref name="Juxtapid FDA label">{{cite web | title=Juxtapid- lomitapide mesylate capsule | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e4c45bb5-15f4-437e-ab98-a649b3676d14 | access-date=27 January 2021}}</ref>
| legal_EU = Rx-only
| legal_EU_comment = <ref name="Lojuxta EPAR" />
| legal_status =

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| index2_label = mesylate
| IUPHAR_ligand = 7439
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 182431-12-5
| CAS_number2 = 202914-84-9
| PubChem = 9853053
| PubChem2 = 11274333
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB08827
| DrugBank2 = DBSALT000110
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 8028764
| ChemSpiderID2 = 9449335
| UNII_Ref = {{fdacite|correct|FDA}} | UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 82KUB0583F | UNII = 82KUB0583F
| UNII2 = X4S83CP54E
| verifiedrevid = 443292980
| IUPAC_name = <nowiki>N-(2,2,2-Trifluoroethyl)-9-2-yl]carbonyl]amino]-1-piperidinyl]butyl]9H-fluoren-9-carboxamde</nowiki>
| image = AEGR-733 structure.svg
| CAS_number = 182431-12-5
| CAS_supplemental = <br />{{CAS|202914-84-9}} (])
| ATC_prefix = none
| ATC_suffix =
| ATC_supplemental =
| PubChem =
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| KEGG_Ref = {{keggcite|correct|kegg}} | KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D09637 | KEGG = D09637
| KEGG2 = D09638
| synonyms = AEGR-773, BMS-201038
| ChEBI_Ref = {{ebicite|changed|EBI}}
| chemical_formula =
| ChEBI = 72297
| ChEBI2 = 72299
| ChEMBL = 354541
| ChEMBL2 = 2105662
| synonyms = AEGR-773, BMS-201038

<!--Chemical data-->
| IUPAC_name = ''N''-(2,2,2-Trifluoroethyl)-9-2-yl]carbonyl]amino]-1-piperidinyl]butyl]-9''H''-fluoren-9-carboxamide
| C=39 | H=37 | F=6 | N=3 | O=2 | C=39 | H=37 | F=6 | N=3 | O=2
| smiles = FC(F)(F)c5ccc(cc5)-c1ccccc1C(=O)NC4CCN(CC4)CCCCC2(C(=O)NCC(F)(F)F)c3ccccc3-c6ccccc26
| molecular_weight = 693.719 g/mol
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| smiles = FC(F)(F)c5ccc(cc5)-c1ccccc1C(=O)NC4CCN(CC4)CCCCC2(C(=O)NCC(F)(F)F)c3ccccc3-c6ccccc26
| StdInChI = 1S/C39H37F6N3O2/c40-38(41,42)25-46-36(50)37(33-13-5-3-10-30(33)31-11-4-6-14-34(31)37)21-7-8-22-48-23-19-28(20-24-48)47-35(49)32-12-2-1-9-29(32)26-15-17-27(18-16-26)39(43,44)45/h1-6,9-18,28H,7-8,19-25H2,(H,46,50)(H,47,49)
| bioavailability =
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| protein_bound =
| StdInChIKey = MBBCVAKAJPKAKM-UHFFFAOYSA-N
| metabolism =
| elimination_half-life =
| excretion =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category=
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = Investigational
| routes_of_administration = Oral
}} }}


'''Lomitapide''' (]) is an investigational drug for the treatment of ], developed by ].<ref name="Spreitzer">{{cite journal '''Lomitapide''' , sold under the brand name '''Juxtapid''' in the US and '''Lojuxta ''' in the EU, is a medication used as a ] for the treatment of ], developed by Aegerion Pharmaceuticals.<ref name="Spreitzer">{{cite journal
| author = H. Spreitzer | author = H. Spreitzer
| date = 12 March 2007 | date = 12 March 2007
| title = Neue Wirkstoffe – BMS-201038 | title = Neue Wirkstoffe – BMS-201038
| journal = Österreichische Apothekerzeitung | journal = Österreichische Apothekerzeitung
| issue = 6/2007 | issue = 6/2007
| pages = 268 | pages = 268
| language = German | language = German
}}</ref> It has been tested in ] as single treatment and in combinations with ], ] and ].<ref>{{cite journal | vauthors = Horwich TB, Fonarow GC | title = Measures of obesity and outcomes after myocardial infarction | journal = Circulation | volume = 118 | issue = 5 | pages = 469–71 | date = July 2008 | pmid = 18663098 | doi = 10.1161/CIRCULATIONAHA.108.792689 | doi-access = free }}</ref><ref>{{cite web | url = http://www.pr-inside.com/aegerion-pharmaceuticals-inc-announces-aegr-r904473.htm | title = Aegerion Pharmaceuticals, Inc. Announces AEGR-733 Phase II Data Demonstrates Significant Lowering of LDL Cholesterol with Promising Hepatic Safety Profile | work = Business Wire | date = 9 November 2008 | archive-url = https://web.archive.org/web/20120229092512/http://www.pr-inside.com/aegerion-pharmaceuticals-inc-announces-aegr-r904473.htm | archive-date=2012-02-29 }}</ref>
}}</ref>
It has been tested in several Phase II ] as single treatment and in combinations with ], ] and ].<ref>{{cite journal|last=Samaha|first=Frederick F|coauthors=James McKenney, LeAnne T Bloedon, William J Sasiela, Daniel J Rader|date=2008|title=Impact of the MTP-Inhibitor, AEGR-733, as Monotherapy and in Combination with Ezetimibe on Lipid Subfractions as Measured by NMR Spectroscopy|journal=Circulation|volume=118|pages=469|pmid=18663098|issue=5|doi=10.1161/CIRCULATIONAHA.108.792689}}</ref><ref></ref>


The US Food and Drug Administration (FDA) approved lomitapide in December 2012, as an ] to reduce ], total ], ], and ] in people with ] (HoFH).<ref>{{cite web | url = https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333285.htm | archive-url = https://web.archive.org/web/20130128180135/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333285.htm | archive-date = 28 January 2013 | title = FDA approves new orphan drug for rare cholesterol disorder | publisher = U.S. Food and Drug Administration }}</ref>
A Phase III trial has started in December 2007 and will be running until August 2011.<ref>{{ClinicalTrialsGov|NCT00730236|A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)}}</ref>

In July 2013, the European Commission approved lomitapide as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low density lipoprotein (LDL) ] in adults with HoFH.<ref name="Lojuxta EPAR">{{cite web | title=Lojuxta EPAR | website=] (EMA) | url=https://www.ema.europa.eu/en/medicines/human/EPAR/lojuxta | access-date=27 January 2021}}</ref>


==Mechanism of action== ==Mechanism of action==
Lomitapide inhibits the ] (MTP or MTTP) which is necessary for ] (VLDL) assembly and secretion in the liver.<ref name="Spreitzer" /><ref name="pmid17215532">{{pmid|17215532}}</ref> Lomitapide inhibits the ] (MTP or MTTP) which is necessary for ] (VLDL) assembly and secretion in the liver.<ref name="Spreitzer" /><ref name="pmid17215532">{{cite journal | vauthors = Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, Millar JS, Ikewaki K, Siegelman ES, Gregg RE, Rader DJ | display-authors = 6 | title = Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia | journal = The New England Journal of Medicine | volume = 356 | issue = 2 | pages = 148–56 | date = January 2007 | pmid = 17215532 | doi = 10.1056/NEJMoa061189 | doi-access = free }}</ref>

In December 2012, drug manufacturer Aegerion announced they had been approved by the FDA to as "an adjunct to a low-fat diet and other lipid-lowering treatments...in patients with homozygous familial hypercholesterolemia (HoFH)."<ref>{{cite web|title=FDA Approves Juxtapid for Homozygous Familial Hypercholesteolemia|url=http://www.dailyrx.com/juxtapid-reduces-cholesterol-patients-homozygous-familial-hypercholesterolemia|date=26 December 2012|access-date=1 January 2013|archive-url=https://web.archive.org/web/20121229140605/http://www.dailyrx.com/juxtapid-reduces-cholesterol-patients-homozygous-familial-hypercholesterolemia|archive-date=29 December 2012|url-status=dead}}</ref><ref>{{cite press release | url = http://ir.aegerion.com/releasedetail.cfm?ReleaseID=728650 | title = FDA Approves Aegerion Pharmaceuticals' Juxtapid (lomitapide) Capsules for Homozygous Familial Hypercholesterolemia (HoFH) | publisher = Aegerion Pharmaceuticals | date = 24 December 2012 | access-date = 1 January 2013 | archive-url = https://web.archive.org/web/20160922115515/http://ir.aegerion.com/releasedetail.cfm?releaseid=728650 | archive-date = 22 September 2016 | url-status = dead }}</ref>


==Side effects== ==Side effects==
In a Phase II study, lomitapide lead to elevated ] levels and fat accumulation in the liver.<ref name="pmid17215532" /> In a ], lomitapide led to elevated ] levels and fat accumulation in the liver.<ref name="pmid17215532" />


==References== == References ==
{{Reflist}} {{Reflist}}


== External links ==
]
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/lomitapide | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Lomitapide }}
]

{{Lipid modifying agents}}
{{Portal bar | Medicine}}

] ]
] ]
] ]
] ]
] ]
]

]

]
{{cardiovascular-drug-stub}}
]

]
Lomitapide: Difference between revisions Add topic